Measles & Rubella Initiative Partners meeting September 7-8, 2017

Slides:



Advertisements
Similar presentations
GIM meeting Feb |1 | Global Action Plan for Prevention and Control of Pneumonia (GAPP) and progress S. Qazi and T Cherian On behalf of the GAPP.
Advertisements

Global Measles and Rubella Strategic Plan
Immunization Services DR. KANUPRIYA CHATURVEDI DR.S.K. CHATURVEDI.
Critical conversations in Public-private partnerships Dr Ranjana Kumar 1 st November 2007.
Working Together to Improve Global Health
Maternal, neonatal, child health and nutrition
Challenges in Measles Outbreak Responses MSF Perspectives Florence Fermon - Myriam Henkens 10th Annual Measles Initiative Meeting 14/09/2011.
A global partnership to stop measles & rubella The Measles & Rubella Initiative: Preparing for the Next Decade Lisa Cairns, MD, MPH Sept 18, 2012 Washington,
Comprehensive M&E Systems
Donor Meeting: Health Update 14 th June, Health Sector Response Total Beneficiaries – estimated 25 Million Total Funds Used – US$ 156 Million Activities:
The partners,initiatives, alliances, groups and meetings within world of the Expanded Programme on Immunization Quick overview 25-September-2012 GID presentation.
Global Measles and Rubella Management Meeting Progress and Challenges in Bangladesh March, 2011 Geneva, WHO HQ Dr Serguei Diorditsa.
Routine Immunization: The Missed Child Perspective Maya van den Ent, PharmD MPH Edward Hoekstra, MD, MSc David Brown, DSc, MScPH, MSc Halima Dao, MD, MSc.
Civil Society in Decision Making for Immunization Policies: the example of National Immunization Technical Advisory Groups (NITAGs) Center for Vaccine.
A Comprehensive Policy framework for the National Immunization Programme Dr Nihal Abeysinghe, [M.B.,B.S., MSc, M.D.] Chief Epidemiologist, Ministry of.
1 The New Public Health Agency of Canada Association of Public Health Epidemiologists in Ontario 2004 Annual Conference October 4, 2004.
Progress towards Sustainable Measles Mortality Reduction South-East Asia Region Jayantha Liyanage Medical Officer- EPI Immunization and Vaccine Development.
1 1 Measles elimination and rubella control in the SEA Region- a brief Update 12 th Annual Meeting of the Measles Rubella Initiative (MRI) September,
Outline Background Objectives and activities GPEI assets
Multi-Year Plans Strengthening immunization systems and introduction of hepatitis B vaccine in Central Europe and the Newly Independent States St. Petersburg,
Polio Eradication  Although the number of endemic countries is at an all-time low in 2002, the actual number of cases was approximately four times higher.
Edward J. Hoekstra, MD, MSc Edward J. Hoekstra, MD, MSc Senior Health Advisor Senior Health Advisor UNICEF HQ, New York UNICEF HQ, New York Peter Strebel,
DRAFT V1 National Vaccine Supply Chain Innovations: Country Commitment to Ownership, Sustainability & Impact GAVI Partners’ Forum WHO – UNICEF – GAVI -
Palestine Bahrain Global Measles and Rubella Management Meeting Boubker Naouri March, 2011 Geneva, WHO HQ.
Current Status of Immunization Service Delivery in Africa Mary Harvey AFR/SD/HRD SOTA/PHN Meeting June 13, 2002.
Conclusions of the meeting and closing remarks. Chronology 1981Hepatitis B vaccine becomes available 1991World Health Assembly resolution call for the.
Measles Initiative Management and Financing September 13, 2011.
1 1 Bose: SEAR Highlights and Priorities Global Measles & Rubella Management Meeting Geneva, March 2011 Accelerated Measles Control: Highlights and.
Funding Update: 2013 – 2015 September 10,
WHO Regional Office for Europe Update on WHO GAVI European Regional Working Group and hepatitis B Immunization Viral Hepatitis Prevention Board Meeting.
Global Overview of Measles & Rubella 11 th Annual Meeting The Measles Initiative Washington, DC th September, 2012.
Dr, Janbaz Afridi Deputy Director EPI Khyber Pakhtunkhwa
1 |1 | Measles pre-elimination and resurgence in the African region Balcha Masresha IVD AFRO Global Measles Management Meeting Geneva March 2011.
WHO / World Bank videoconference 19 September 2008
Status of EPI In Guinea DR. Mariama BAH Child Survival Advisor USAID/Guinea June 13, 2002.
WHO EURO In Country Coordination and Strengthening National Interagency Coordinating Committees.
India: Transitioning of Polio Network to Support Other Immunization Activities Jeffrey W McFarland, MD Regional Advisor, WHO South-East Asia Regional Office.
Sudan EPI Benefits From Polio Eradication Program M&RI Annual Partners Meetings Washington D.C September 2015 Sudan EPI Benefits From Polio Eradication.
Update on Progress toward Measles Situation in EMR September 2008 Dr B. Naouri VPI/DCD/EMRO.
Zika Response Strategy
Measles Mortality Reduction: the risk of resurgence Global Immunization Meeting Geneva, Switzerland 1-3 February 2010 Balcha Masresha, WHO/AFRO.
A global partnership to stop measles & rubella 1 Measles & Rubella Initiative --Who We Are-- Stephen Cochi, MD, MPH Global Immunization Division Centers.
12 th Annual Meeting of The Measles & Rubella Initiative American Red Cross, Washington, DC September, 2013.
Sustaining the gains and reaching milestones on the way towards elimination of measles and rubella 15 September 2015 Dr Peter Strebel, WHO, IVB/EPI.
Measles and Rubella Initiative Financial Resource Requirements for Measles and Rubella Annual Partners Meeting, September
Vaccine Development, Innovations and Investments Oslo Malaria Conference, “Getting To Zero” Jean Stéphenne, Chairman and President GlaxoSmithKline Biologicals.
Midterm Review Update Global Measles and Rubella Strategic Plan 2012 – 2020 W. A. Orenstein, MD Measles and Rubella Management Meeting, Geneva, June 2016.
GAVI’S NEW MEASLES AND RUBELLA STRATEGY Dr. Khin Devi Aung Gavi Secretariat 21 June 2016, Geneva 1 #vaccineswork.
Positioning Africa for effective preparedness & response to emerging viral diseases Dr Ibrahima Soce Fall, WHO-Regional Office for Africa-AFRO Brazzaville-Congo.
Measles & Rubella Initiative Advocacy & Communication
Global Measles and Rubella: Highlights, Priorities and Critical Issues
Response to the Yellow Fever Outbreak in the WHO African Region: What has been done? Dr Ambrose Talisuna, WHO-Regional Office for Africa-AFRO Brazzaville-Congo.
Vaccine-Preventable Disease Surveillance: Why is it important?
Session 4 Cross Cutting MR and RI Priorities Introduction
Technical Consultation: Folate Status in Women and NTD Risk-Reduction
Global Overview of Measles
Midterm Review of the Global Measles and Rubella Strategic Plan 2012 – 2020 Summary of the Findings and Implementation Status Dr Kaushik Banerjee M&RI.
World Health Organization
Progress and Challenges with achieving Universal Immunization Coverage
Session 1: New Opportunities and New Direction
Stakeholder Consultation
African Region- priorities to reach the 2020 measles elimination goal.
Experience with the measles outbreak response fund
Funding Update: Current Situation and Future Prospects
Overview of Polio Legacy Transition Planning
The potential polio dividend
State of Measles Initiative Financing Partners for Measles Advocacy Meeting Washington, D.C. September 22, 2008 Andrea Gay.
Partners for Measles Advocacy—7th Annual Meeting
YELLOW FEVER VACCINE AVAILABILITY AND NEEDS FOR THE AFRICAN REGION
Comprehensive M&E Systems
Presentation transcript:

Measles & Rubella Initiative Partners meeting September 7-8, 2017 Polio Transition Planning: Risks and opportunities of transitioning polio resources to support Measles-Rubella Elimination Measles & Rubella Initiative Partners meeting September 7-8, 2017

Underlying premise: Transition to other health goals risk -- and opportunity There is a RISK to other health goals (such as Measles-Rubella) when GPEI funding stops, as the polio infrastructure is already helping to support other health programmes There is an OPPORTUNITY for current GPEI staff, assets and knowledge to further contribute to other health goals 2

Measles & Rubella Global Strategic Plan Midterm Review (2016) “All stakeholders involved in control and elimination of measles and rubella as well as those involved in immunization system strengthening should engage in polio transition planning (at all levels) to leverage the opportunity and avoid the risks of the end of the GPEI”

Most Obvious Candidates for Transitioning of Polio Assets* Measles and rubella elimination Immunization system strengthening Vaccine preventable-communicable disease surveillance & lab networks * adapted from WHO draft report on Polio Transition Planning to the 70th WHA, April 2017

GVAP national and subnational vaccination coverage targets KEY STEP to build immunization program capacity is to strategically link: 1. disease-specific efforts 2. health system strengthening efforts GVAP measles and rubella elimination targets GVAP national and subnational vaccination coverage targets Orenstein W.A. & Seib K (2016) Beyond vertical and horizontal programs: a diagonal approach to building national immunization programs through measles elimination, Expert Review of Vaccines, 15:7, 791-793 Sepúlveda J et al. Improvement of child survival in Mexico: the diagonal approach. Lancet 2006; 368: 2017–27

GPEI presence in over 70 countries, but 95% of personnel footprint in 16 countries M&RI – 6 Gavi priority Includes social mobilizers. Does not include national government staff, vaccinators or regional/headquarters personnel. Note: Philippines, Haiti also have between 1-10 polio funded personnel but are not displayed; no headquarters staff displayed Source: GPEI partner HR databases, 2014 Country-level Transition Planning | Transition Independent Monitoring Board

Characteristics of the 16 Priority “Polio Transition” Countries Most of the world’s unvaccinated and under-vaccinated children (53% of 20.8 million infants who did not receive measles vaccine in 2015 are in the Big 6 priority measles countries) Most of the world’s measles cases and deaths (88% of deaths) Most of the world’s rubella and congenital rubella syndrome (100,000 CRS cases) Consequences of losing polio assets – risk that EPI progress in these countries and globally will be reversed !!

Example: Polio funds 70% of Polio funding plays a significant role in overall partner capacity in many regions and countries Example: Polio funds 70% of WHO staff in DR Congo1 86% of WHO immunization personnel in Africa are polio-funded 40% of WHO AFRO’s workforce is polio-funded 38 126 3 88 Provinces Kinshasa # polio-funded personnel# polio-funded personnel Other Total staff1 1. 2013 DRC FRR data; excluding consultants Source: GPEI FRR, WHO, UNICEF, BCG analysis Country-level Transition Planning | Transition Independent Monitoring Board © Bill & Melinda Gates Foundation

Why It Makes Sense to Pivot from Polio Eradication to Measles-Rubella Elimination Strategies are similar Surveillance and lab network Outbreak preparedness and response Importance of achieving/maintaining high routine coverage Need for periodic SIAs to reach inaccessible children Use of communications/social mobilization network Polio infrastructure concentrated in the lowest-performing countries with highest measles-rubella disease burden Polio and measles-rubella already working together and interconnected including human resources Measles still major cause of <5 child deaths Rubella is the leading infectious cause of birth defects

GPEI Lessons Learned That Can Be Applied to Measles-Rubella Elimination Using a targeted disease initiative for broader health communication Value of advanced state-of-the-art global lab network and real-time disease surveillance Experience with reaching every child Outstanding program monitoring and use of accountability frameworks for performance assessment Partnership coordination, advocacy, resource mobilization

Polio-Funded Surveillance Officer Responsibilities Other VPDs: Measles/Rubella Yellow Fever Neonatal tetanus Meningitis Acute encephalitis syndrome Diphtheria Cholera Pertussis …and so on Other Communicable Diseases: Bloody diarrhea Neglected tropical diseases Dengue Viral hemorrhagic fevers Rabies Malaria ….and so on Other VPDs

Health Emergency and IHR Capacity: Building on the Polio/MR Lab and Surveillance Network (>700 labs) The GMRLN started in 2000, and is now the largest globally-coordinated laboratory network supporting surveillance in 191 countries 723 GMRLN labs in 165 countries include: 506 subnational 180 national 14 regional reference 3 global specialized laboratories 12

Resource Dependence of MR on Polio Financial Polio FRR: surveillance/lab costs $102 million, excluding technical support like NPSP (2016) $111 million annually needed for MR surveillance to be maintained at status quo (excluding operational costs at country level) $77 million (70%) coming from polio $$ Human Over 2500 polio-funded staff are supporting MR surveillance

Key Messages– Polio/MR/VPD Surveillance World Health Organization 18 September, 2018 Key Messages– Polio/MR/VPD Surveillance Polio is the foundation for much of VPD surveillance in many developing countries Polio funds a significant amount of the VPD surveillance -- human resources and infrastructure Even with polio support, insufficient to achieve various global/regional goals Careful planning and consideration needs to be undertaken to ensure all the gains in VPD surveillance are not destroyed during polio transition Polio needs VPD surveillance as much as VPD surveillance needs polio Not as vertical as previously accused